Best GLP-1 Medications for Weight Maintenance After Reaching Goal Weight
You lost the weight. Now comes the harder part: keeping it off. Here's the clinical playbook for GLP-1 maintenance dosing, tapering, and the providers that won't lock you into a contract you no longer need.
The Rebound Problem: Why 67% of People Regain the Weight
The most sobering data point in obesity medicine comes from the STEP 1 extension trial. When patients who had lost an average of 17% body weight on semaglutide were switched to placebo, they regained approximately two-thirds of their lost weight within 12 months.
This is not a failure of willpower. It is a physiological reality. Obesity is now classified by every major medical organization as a chronic, relapsing disease—similar to hypertension or Type 2 diabetes. The biological drivers that caused the weight gain in the first place (leptin resistance, ghrelin dysregulation, reduced metabolic rate, altered gut microbiome) do not disappear when the weight comes off. They are suppressed by the medication. Remove the medication, and these drivers re-emerge.
Understanding this is critical for anyone who has reached their goal weight on a GLP-1 and is now wondering: "Can I stop?"
The Science of Weight Regain After GLP-1 Therapy
To understand why maintenance dosing works, you need to understand the three biological forces that drive weight regain:
1. Metabolic Adaptation
When you lose a significant amount of weight (15%+ body weight), your resting metabolic rate (RMR) drops disproportionately. A man who weighed 250 lbs and now weighs 210 lbs does not burn calories at the rate of a man who has always been 210 lbs. His body burns fewer calories than expected—a phenomenon called "metabolic adaptation" or "adaptive thermogenesis." This metabolic penalty can persist for years after weight loss and creates a constant caloric surplus even when eating what appears to be a normal amount of food.
2. Hormonal Rebound
Ghrelin (the hunger hormone) surges after weight loss. Leptin (the satiety hormone) drops dramatically because there is less fat tissue producing it. The net result is a powerful, physiological increase in appetite that can persist for 12-24 months after reaching goal weight. GLP-1 medications directly counteract this hormonal rebound by suppressing appetite through the hypothalamus.
3. Neural Re-Sensitization
During active weight loss on a GLP-1, the brain's dopamine reward pathways are blunted. Food loses its addictive pull. When the medication is removed, these pathways re-sensitize rapidly—often within weeks. Patients describe the return of "food noise," cravings, and compulsive eating patterns they thought were permanently resolved.
The Maintenance Dosing Protocol
The goal of maintenance therapy is to use the minimum effective dose of medication to prevent hormonal rebound and metabolic regain while minimizing cost and side effects.
Phase 1: Goal Weight Reached (Weeks 1-4)
Continue your current dose for at least 4 weeks after reaching goal weight. Your body needs time to stabilize at its new set point. Do not begin tapering immediately.
Phase 2: Initial Taper (Weeks 5-12)
Reduce dose by one step. For semaglutide: drop from 2.4mg to 1.7mg (or from 1.7mg to 1.0mg). For tirzepatide: drop from 15mg to 10mg (or 10mg to 7.5mg). Monitor weight weekly. If weight remains stable (±2 lbs), proceed to Phase 3.
Phase 3: Maintenance Dose (Months 3-12)
Continue reducing until you find the lowest dose that maintains weight stability. Many patients stabilize at semaglutide 0.5mg or tirzepatide 2.5-5mg weekly. This is your maintenance dose. Stay here for at least 6-12 months.
Phase 4: Discontinuation Attempt (Optional, 12+ Months)
After 12+ months of stable maintenance, some physicians will attempt a supervised discontinuation. The patient stops medication entirely while monitoring weight weekly. If more than 5 lbs are regained in 4 weeks, the maintenance dose is resumed immediately.
Maintenance Dose Comparison Table
| Medication | Active Loss Dose | Typical Maintenance Dose | Monthly Cost (Compounded) |
|---|---|---|---|
| Semaglutide | 1.7-2.4mg weekly | 0.25-0.5mg weekly | $146 (Telehealth FX) |
| Tirzepatide | 10-15mg weekly | 2.5-5mg weekly | $146 (Telehealth FX) |
| Wegovy (brand) | 2.4mg weekly | 1.7mg weekly | $1,349/mo retail |
| Zepbound (brand) | 15mg weekly | 5-10mg weekly | $1,060/mo retail |
Why No-Contract Providers Matter for Maintenance
During the active weight loss phase, committing to a multi-month program makes sense. You are investing in a transformation. But during maintenance, the calculus changes entirely.
Maintenance is inherently unpredictable. Some patients maintain beautifully on a low dose for years. Others successfully discontinue after 12 months. Still others need to cycle on and off depending on life stressors, seasonal patterns, or hormonal changes.
Being locked into a $300+/month contract with a 6-month minimum during maintenance is financially wasteful. What you need is a provider that lets you start and stop on your terms, adjust your dose freely, and pay a flat, affordable rate regardless of whether you're on a high active-loss dose or a minimal maintenance dose.
The Best Telehealth Providers for GLP-1 Maintenance
Telehealth FX is the ideal maintenance provider for one critical reason: the price is the same regardless of your dose. Whether you're on an aggressive 2.4mg semaglutide weight-loss dose or a minimal 0.25mg maintenance dose, the cost is $146/month. No other major provider offers this pricing structure.
This flat-rate model eliminates the perverse incentive that exists at other providers, where staying on a higher (more expensive) dose generates more revenue. At Telehealth FX, your physician can freely titrate you down to the lowest effective maintenance dose without any financial pressure to keep you on more medication than you need.
The no-contract policy is equally important for maintenance patients. If you want to attempt a supervised discontinuation after 12 months, you can simply cancel your subscription. If you need to restart 3 months later because weight is creeping back, you can re-enroll instantly without re-doing the entire intake process or paying a re-activation fee.
Found pairs GLP-1 prescriptions with ongoing behavioral coaching, which can be valuable during the maintenance phase when patients must actively build new habits to replace the medication's appetite suppression. The coaching focuses on mindful eating, stress management, and exercise adherence.
The cost is higher ($99 membership + $149-$249 medication), and Found requires a multi-month commitment. Found primarily offers semaglutide; tirzepatide availability is limited. For patients who need structured accountability beyond just the medication, Found adds genuine value.
PlushCare is a full-service telehealth platform where GLP-1 maintenance can be managed alongside other primary care needs (annual checkups, blood work, referrals). For patients who want a single physician overseeing their metabolic health long-term, PlushCare offers that continuity.
The downside: higher cost ($219/month medication + $15 membership), video calls are required, and tirzepatide availability depends on your state. Not the most cost-effective choice for maintenance alone, but strong for holistic, long-term health management.
The Financial Case for Maintenance vs. Regain
One of the most common reasons patients discontinue GLP-1 therapy after reaching goal weight is cost. "I've lost the weight, why keep paying?" The answer is simple mathematics.
Consider a patient who spent 12 months losing 50 lbs on Telehealth FX at $146/month. Total investment: $1,752. If that patient stops medication and regains 35 lbs over the next year (the statistical median), they will likely need another full 8-10 month course of aggressive dosing to lose it again. That's another $1,168-$1,460.
Contrast that with staying on a maintenance dose at $146/month indefinitely. After 3 years of maintenance, the total cost is $5,256—but the weight never returns, the metabolic benefits compound, and the patient avoids the physical and psychological toll of yo-yo dieting, which is independently associated with increased cardiovascular risk.
For patients on brand-name medications ($1,000+/month), the financial argument against maintenance is understandable. But at $146/month for compounded medication through Telehealth FX, maintenance therapy costs less than most gym memberships, meal delivery services, or the excess food consumed during a weight regain cycle.
The Identity Crisis of Maintenance
An under-discussed challenge of the maintenance phase is psychological. During active weight loss, patients have a clear, measurable goal: the scale is going down, clothes are getting looser, compliments are flowing. There is constant positive reinforcement.
Maintenance offers none of that dopamine. The scale stays the same. Nobody congratulates you for weighing the same thing you weighed last month. The emotional high of transformation is replaced by the mundane reality of sustaining. For patients who derived significant emotional satisfaction from the visible progress of weight loss, this transition can trigger anxiety, depression, or a subconscious desire to stop the medication and "see what happens."
This is why many obesity medicine specialists recommend that patients reframe their relationship with the scale during maintenance. The goal is no longer a number going down. The goal is a number staying stable within a 5-lb range. Success in maintenance is invisible—and that invisibility is the entire point.
Seasonal and Stress-Related Rebound Protocols
Weight maintenance is not a straight line. Even on medication, most patients experience predictable fluctuations tied to seasonal patterns, holidays, and life stressors.
The Holiday Window (November-January)
The average American gains 1-3 lbs during the holiday season. For maintenance patients, this window is the highest-risk period for triggering a full rebound. Many physicians proactively increase the maintenance dose by one step (e.g., from semaglutide 0.5mg to 1.0mg) from mid-November through mid-January, then taper back down. This "seasonal boost" provides additional appetite control during the most food-centric period of the year.
Acute Stress Events
Divorce, job loss, bereavement, and major life transitions trigger cortisol spikes that directly promote visceral fat storage and increase appetite. When a maintenance patient experiences a significant life stressor, a temporary dose increase (for 4-8 weeks) can prevent a stress-driven regain that would otherwise take months to reverse.
This is another reason why no-contract providers are essential for maintenance. You need the flexibility to adjust your dose month-to-month based on real-life circumstances, not a rigid protocol designed for the "average" patient.
Medication alone cannot maintain weight loss indefinitely. The maintenance phase requires deliberate lifestyle modifications that become the "new normal" even if the medication is eventually discontinued.
Protein-First Eating
Maintain protein intake at 1.0-1.2g per kilogram of body weight daily. Protein preserves lean muscle mass (which drives metabolic rate), promotes satiety, and has the highest thermic effect of any macronutrient. During maintenance, when appetite gradually increases as doses decrease, protein becomes your primary tool for staying full.
Resistance Training (Non-Negotiable)
Continue strength training 3-4 times per week. Muscle tissue is the single largest determinant of resting metabolic rate. Every pound of muscle you preserve during the transition from active loss to maintenance directly combats the metabolic adaptation that drives regain.
Daily Weigh-Ins
The National Weight Control Registry—which tracks over 10,000 individuals who have maintained 30+ lbs of weight loss for over a year—consistently identifies daily weighing as one of the strongest predictors of long-term maintenance success. The scale provides early warning. A 3-5 lb increase over 2 weeks is the signal to consult your physician about adjusting your maintenance dose before a full regain occurs.
It is important to understand that daily weight fluctuations of 1-3 lbs are completely normal and driven by hydration, sodium intake, bowel movements, and hormonal cycles (in women). The number to watch is the 7-day moving average. If your weekly average trends upward for two consecutive weeks, take action.
Sleep Optimization
Poor sleep (less than 7 hours) elevates ghrelin, suppresses leptin, increases cortisol, and drives insulin resistance. For maintenance patients, sleep is a metabolic lever. Prioritize 7-9 hours of quality sleep. If you have untreated sleep apnea, address it—weight loss may have improved but not fully resolved it.
Research from the University of Chicago found that sleep-restricted individuals on a caloric deficit lost 55% less fat and 60% more lean muscle mass compared to well-rested controls. During maintenance, when the margin for error is slim, adequate sleep is not a luxury—it is a metabolic requirement.
Step Count as a Metabolic Floor
Non-Exercise Activity Thermogenesis (NEAT)—the calories burned through fidgeting, walking, standing, and daily movement—accounts for a surprisingly large portion of total daily energy expenditure. Maintaining a daily step count of 8,000-10,000 steps provides a consistent metabolic "floor" that helps offset the reduced resting metabolic rate that accompanies weight loss. Track steps daily and treat it as non-negotiable as taking your medication.
Protect Your Progress
Access compounded Semaglutide or Tirzepatide maintenance doses for $146/month. No contracts. Adjust your dose freely. Cancel and restart anytime.
Start Maintenance with Telehealth FX →Frequently Asked Questions
Clinical data from the STEP 1 extension trial shows that approximately two-thirds of patients regain a significant portion of lost weight within 12 months of stopping semaglutide entirely. This reflects the biological reality that obesity is a chronic condition requiring ongoing management, not a moral failure.
Yes. Many physicians prescribe a reduced maintenance dose (0.25-0.5mg weekly for semaglutide, or 2.5-5mg for tirzepatide) after patients reach goal weight. This lower dose provides enough appetite regulation to prevent rebound without the aggressive effects of higher doses. Telehealth FX charges the same $146/month regardless of dose.
Both are effective. Tirzepatide may offer a slight advantage due to its dual GIP/GLP-1 mechanism providing stronger insulin sensitivity at lower doses. The best choice depends on which medication you used during active weight loss and how your body responded.
Brand-name maintenance doses cost $800-$1,349/month out of pocket. Compounded maintenance doses through Telehealth FX cost $146/month for either semaglutide or tirzepatide at any dose level, making indefinite maintenance financially realistic.
The current clinical consensus recommends a minimum of 6-12 months of maintenance therapy before attempting a supervised taper. Some patients benefit from indefinite low-dose therapy. The decision should be made collaboratively between patient and physician based on weight stability, lifestyle factors, and metabolic markers.